Protagenic Therapeutics Inc.
09/18/2024 | Press release | Distributed by Public on 09/18/2024 04:01
Material Event Form 8 K
Item 8.01 Other Events.
The Company has updated its currently anticipated clinical development milestones for PT00114:
| ● | Q4 2024 Commence multiple dose portion of Phase I study for PT00114 | |
| ● | Q2 2025 Public availability of results from multiple dose portion of Phase I study for PT00114 | |
| ● | Q3 2025 Initiation of Phase IIa study for PT00114 |
The Company will provide further updates to its clinical development schedule as it becomes clearer.